Cascadian Therapeutics’ Tucatinib Receives Orphan Drug Designation from FDA

Cascadian Therapeutics tucatinib was granted an Orphan Drug designation by the FDA for the treatment of breast cancer patients with brain metastases.

Tucatinib is a tyrosine kinase inhibitor that is highly selective for HER2 without significant inhibition of EGFR.

The company is currently enrolling patients into the study in the United States and Canada. Clinical sites in Western Europe, Australia and Israel are expected to open this year.